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ABSTRACT
While there is an extensive literature on the use of psychotropic medications among
individuals with mental retardation, little of it has focused on the reasons for these prescriptions.
Researchers have shown that the prevalence of psychotropic medication use among individuals with
mental retardation is relatively high when compared to people with other disabilities and that the
reasons for these drug prescriptions may not be based on rational pharmacotherapy. Data is needed
on the prescribing physician’s adherence to consensus guidelines or algorithms developed to
enhance rational psychopharmacotherapy. In order to do this, the rationales being used by
physicians when they decide to prescribe a medication must first be examined. The current study
examines the approaches to medication prescription taken by physicians at one state facility. The
results of this study showed that physicians at this particular facility for individuals with
developmental disabilities typically used a primary illness approach in prescribing psychotropic
medication. The results also showed that, in general, the documentation in the charts regarding
assessments, diagnostic formulation, differential diagnosis, and rationale of pharmacotherapy was
not very clear or missing. The limitations of this study are discussed as well as implications for
future research.
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INTRODUCTION
Psychotropic medications are prescribed to treat a myriad of behavioral and psychiatric
symptoms in both the general population and in individuals with mental retardation (Advocat,
Mayville, & Matson, 2000; Singh & Winton, 1989; Young & Hawkins, 2002). In the field of mental
retardation, psychotropic medications are typically used to reduce maladaptive behavior such as
aggression, pica, property destruction, and self-injury (Aman, Singh, & Fitzpatrick, 1987; Aman,
Singh, & White, 1987; Intagliata & Rinck, 1985). As such, individuals with mental retardation may
be prescribed psychotropic medication for suppressing behavior rather than treating a psychiatric
disorder (Aman & Singh, 1991).
As many individuals with mental retardation are non-verbal, they must find other means to
communicate or control their environment. Researchers suggest that individuals with mental
retardation who have limited communication skills use expressive behavior to communicate their
wants and needs (Dura, 1997; Durand & Carr, 1991). In fact, limited communication skills can lead
to communication in the form of aggression, self-injury, or self-stimulatory behavior (Menolascino,
Levitas, & Greiner, 1986). Therefore, aggression, property destruction, self-injury and other socially
inappropriate behaviors may serve a functional purpose for an individual (Carr & Durand, 1985).
As psychotropic medications may cause side effects that cause some degree of behavioral or
cognitive impairment, these drugs may be suppressing the individuals’ ability to functionally
communicate (Lowry & Sovner, 1991).
Research on the functional aspects of an individuals’ behavior, determining what motivates
an individual to engage in a particular behavior, has yielded several technologies designed for
assessing an individual’s behavior. Assessment techniques based on various operant procedures
include functional analysis (Iwata, Dorsey, Slifer, Bauman, & Richman, 1982), functional assessment
(Hile & Desrochers, 1993), functional communication training (Carr & Durand, 1985), and positive
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behavior supports (Carr et al., 2002). The aim of these assessments is to determine the function of
an individual’s behavior and use this information to design interventions that teach the individual
socially appropriate, functionally alternative replacement behaviors. The efficacy of these behavioral
assessment methods has been documented in the literature. However, teaching an individual the
new skills they need relies on the individual being able to learn. As mental retardation is primarily a
learning disorder and psychotropic medications may impair learning, these medications may reduce
an individual’s chances for success and negatively impact on their quality of life (Lowry & Sovner,
1991). Given the existence of procedures that teach individuals skills that enable them to
communicate appropriately and effectively, it may not be appropriate to treat problems that are
behavioral and functional in nature with psychotropic medication.
Literature on psychotropic medication has strongly indicated a link to an increased risk of
serious side effects; of particular concern to individuals with mental retardation are side effects that
may interfere with learning (Advocat, Mayville, & Matson, 2000; Maxmen & Ward, 2002;
Schatzberg, Cole & DeBattista, 2003). Some of these side effects include cognitive slowing, loss of
creativity, memory problems, confusion, sedation, akathisia, akinesia, noncompliance and blurred
vision (Baumeister, Sevin, King, 1998; Janicak, Davis, Preskorn, & Ayd, 2001; Schatzberg, Cole &
DeBattista, 2003). Further, as individuals with mental retardation generally have more health
problems than individuals without, the risk of side effects among individuals with mental retardation
is greater and further reaching and the use of psychotropic medication needs to be approached more
carefully (Janicki et al., 2002; Mulligan Ault, Guy, Rues, Noto, & Guess, 1994; Springer, 1987).
However, this does not seem to be the case. For example, one study found that 62% of individuals
in their sample were prescribed psychotropic medications without a valid documented psychiatric
diagnosis (Bisconer, Sine, & Zhang, 1996). This case may not be an isolated one.
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While a body of literature on the use of psychotropic medications among individuals with
mental retardation exists, it is limited in that it has been focused primarily on prevalence rates and
patterns of prescription rather than on the primary reasons for drug prescription (Young &
Hawkins, 2002). Few studies have examined why individuals with mental retardation are prescribed
psychotropic medications, and fewer have examined the legitimacy of these prescriptions. Unless a
careful and thorough assessment indicates that an individual with mental retardation engages in
behavior problems that are a feature of an underlying mental illness that may be responsive to
psychotropic drug therapy, the use of these drugs should be considered inappropriate treatment to
control an individual’s behavior (Sovner, 1989). In fact, it may be considered a form of chemical
restraint if the medication is prescribed solely for behavioral control and to such a point they cannot
learn or function. For psychotropic medication prescription to be considered legitimate, it should
target the behavioral end-point(s) of a specific psychiatric disorder as defined in the DSM-IV-TR
(APA, 2000), or have a specific behavioral-psychopharmacologic hypothesis.
The practice of prescribing medication for behavioral control tends to ignore the bidirectionality of drug and psychosocial interventions. For example, self-injury has been shown to
respond to both pharmacological and behavioral treatments (Mace, Blum, Sierp, Delaney, & Mauk,
2001). Behavioral treatments operate on the premise that the behavior is controlled and maintained
by the environment. Pharmacological treatments are based on the hypothesis that the behavior may
be caused by an underlying chemical imbalance. Thus, a bio-behavioral assessment and diagnostic
system could be used to differentiate between conditions most likely to respond to behavioral
treatments and those most likely to respond to pharmacological treatments. If the assessment
reveals that an individual’s self-injury is a mixed type, that is part behavioral and part biological, then
treatment would consist of both behavioral and pharmacological components. Both behavioral and
drug treatments produce changes in the individual. As these changes are reinforced in the
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individual’s environment, the need for medication can decrease and the need for skills training to
maintain and continue the reduction of the behavioral aspect of self-injury could increase, or vice
versa. This bi-directionality of the effects of interventions is rarely appreciated when
psychopharmacological and non-psychopharmacological interventions are developed for people in
general, let alone individuals with developmental disabilities (Napolitano et al., 1999). The lesson
here is that the impact of all interventions must be constantly evaluated to account for and respond
to changes in the individual and their environment.
The literature on current drug prescribing practices indicates that comprehensive process
and outcome evaluations are rarely performed and the needs of individuals with mental retardation
are not being fully met (Hellings, 1999; Sevin et al., 2001). It is evident that a closer look at the
prescription patterns of psychotropic medications is warranted. Individuals with mental retardation
depend on professionals to teach them the skills they need in order to have the highest quality of life
possible (Matson, Bamburg, Smalls, & Smiroldo, 1997; Menolascino et al., 1986). Simply prescribing
medication to treat behavioral symptomology ignores the fact that drugs do not target the cause of
the behavior problem or the individual’s vulnerability to it. That is, while medications may
physiologically reduce behavioral symptoms, the individual has not learned anything and is still
vulnerable to the internal and external environmental triggers of the particular problem behavior
(Zuckerman, 1999). Using psychotropic medications among individuals with mental retardation
needs to be carefully considered and, if their use is deemed appropriate, they should be monitored
closely to ensure that the individuals are receiving the best possible treatment according to current
best practice.
Ideally, the use of psychotropic medication involves matching specific label and clinically
validated off-label uses of the medication to the specific signs and symptoms of a psychiatric
disorder or a well-defined behavioral target (Reiss & Aman, 1998). Psychotropic medication
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prescriptions should be specific as to what particular signs and symptoms of a disorder are being
targeted. For example, for an individual with depression it is important to know if the medication is
targeting weight loss, insomnia, lethargy, or mood; for ADHD, is the medication targeting
symptoms such as difficulty sustaining attention, being easily distracted, or fidgeting. As
psychotropic medications do not treat entire symptom profiles, it is important to know which
symptoms are being targeted so that supplemental therapies may be introduced to treat other
symptoms that may have a behavioral, or learned, component. In this manner, a clinician can
properly monitor the individual’s progress objectively and ensure that the prescribed treatments are
appropriate. In order to examine how well a particular psychotropic medication fits the individual’s
diagnosis and target symptoms, we must first examine what approaches physicians are taking to
prescribing medications to individuals with mental retardation.
There are three ways of conceptualizing psychopharmacotherapy in people with mental
retardation, including (a) a target symptom approach, (b) a primary illness approach, and (c) a
behavioral-pharmacologic hypothesis approach. The target symptom approach is based on the
notion that if a clinician does not know or cannot unravel the biomedical or behavioral basis of a
target behavior, the behavior can still be treated directly without knowing the underlying cause
(Conner, 2002; Rush & Francis, 2000). For example, aggression that has an explosive and rageful
quality to it and is often seen as a behavioral expression of several psychiatric disorders (e.g.,
conduct disorder in children, antisocial personality disorder in adults) is medication responsive.
Regardless of the actual psychiatric diagnosis, the overt aggression can be treated with psychotropic
medications. For example, overt aggression associated with explosive rage can be treated with
atypical antipsychotic medications and lithium, aggression associated with affective lability can be
treated with mood stabilizers, and those associated with autonomic nervous system (ANS)
overarousal can be treated with adrenergics, Clonidine, Guanfacine and β - blockers. This approach
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is analogous to palliative medical treatment when the underlying medical illness is not known or not
treatable.
The primary illness approach assumes that we can treat the underlying condition, thereby
taking care of the associated symptoms without directly treating them (Conner, 2002; Rush &
Francis, 2000). That is, we can identify the psychiatric disorder that underlies the target behavior
and the psychiatric illness itself is amenable to psychopharmacological treatment. For example, if
the aggression is a behavioral manifestation of the underlying psychosis or mood disorder, then it
will decrease when the underlying psychosis or mood is treated with medication. This treatment is
not palliative, but focused on the underlying disorder.
The behavioral-pharmacologic hypothesis approach is based on the notion that there may be
specific mechanisms that explain the probable genesis and maintenance of a target behavior
(Conner, 2002; Rush & Francis, 2000). For example, aggression (e.g., self-injury) may occur as a
result of an imbalance of endogenous opiates in the body and using naltrexone to restore this
imbalance will reduce or eliminate the aggression.
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PREVALENCE OF PSYCHOTROPIC MEDICATION USE
In 1966, Ronald Lipman undertook the first survey of drug usage among individuals with
mental retardation in institutions. This seminal investigation examined 142 state and 31 private
institutions across the country and found that 51% of residents were prescribed psychotropic
medications. Interestingly, two drugs, specifically thioridazine and chlorpromazine, accounted for
approximately 58% of all psychotropic drug prescriptions and were the two most frequently
prescribed drugs in 91% of the institutions surveyed (Lipman, 1970). Overall, the drug classes that
were prescribed most commonly were major tranquilizers, which accounted for 39.2% of
prescriptions, minor tranquilizers (8.1%), and antidepressants (3.8%). Further, in the institutions
surveyed, 25% of the residents’ prescribed psychotropic medications typically received these drugs
for four years up to an indefinite period of time. While this survey did not examine the issue of
polypharmacy, the prescription of two or more psychotropic medications, Lipman (1970) did find
that maximum dosages above recommendations set by drug manufacturers were common.
This landmark study was followed by several other investigations, with most reporting
similar findings (Singh, Ellis, & Wechsler, 1997). In an effort to update Lipman’s survey Singh, Ellis,
and Wechsler (1997) reviewed drug prevalence studies between 1966 and 1995. This review split the
sample of drug prevalence studies into two time periods, one from 1966 to 1985 and the other from
1986 to 1995. Research performed from 1966 to 1985 had been summarized by other authors, so
Singh et al. (1997) only briefly summarized previous findings. During the first time period, 1966 to
1985, the prevalence of psychotropic drug use in institutions ranged from 19% to 86% with most
studies reporting between 30% and 50%. In the community samples, the prevalence of
psychotropic drug use in adults ranged from 26% to 36%. During the second time period, 1986 to
1995, Singh et al. found that the prevalence of psychotropic drug use in institutions ranged from
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12% to 49%. In community studies, the typical prevalence rate of psychotropic drugs ranged from
19% to 29%.
Since the Singh et al. (1997) review, several studies have been published which examine the
prevalence rates of psychotropic medication use among individuals with mental retardation and have
reported similar findings (e.g., Nottestad & Linaker, 2003; Roberson et al., 2000; Stolker, Koedoot,
Heerdink, Leufkens, & Nolen, 2002). The prevalence of psychotropic drug use in institutions has
been found to range from 25% to 60% (Roberstson et al., 2000). In community settings, the
prevalence rate of psychotropic medication use has been found to range from 20% (Emerson et al.,
1997) to 56% (Roberstson et al., 2000).
As the literature demonstrates, there has not been a significant change in the use of
psychotropic medications among individuals with developmental disabilities since Lipman’s survey
in 1966. This situation is surprising considering the emergence of literature indicating that the use of
such medication in this population is often unnecessary and inappropriate. Further, research has
shown that most of the medications being prescribed to individuals with developmental disabilities
can have serious side effects and cause long term harm. While guidelines for the prescription of
psychotropic medications exist (e.g., American Journal on Mental Retardation, Vol. 105, No. 3; Reiss
& Aman, 1998) the prevalence of these medications suggests that these guidelines are not be being
followed and individuals with mental retardation may be overmedicated.
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PSYCHOTROPIC MEDICATIONS
Psychotropic medications affect specific brain functioning by increasing or decreasing the
activity of neurotransmitters, the chemical messengers of the brain (Diamond, 2002). Some
neurotransmitters trigger the firing of nerve cells and are known as excitatory while others block the
firing of a nerve cell and are known as inhibitory. Medications are designed to either increase or
decrease the activity of specific neurotransmitters. Change in the neurotransmitter pathways cause
changes in brain functions that ultimately lead to changes in an individual’s behavior. As previously
noted, psychotropic medications are used to target behavioral and psychiatric symptoms of mental
illness.
History
The historical origin of the antipsychotic known as Chlorpromazine (CPZ) dates back to
1883 and the synthesis of its parent compound phenothiazine by a German chemist named August
Heinrich (Swazey, 1974). Interestingly, Heinrich was investigating the structural properties of
methylene blue compounds, valuable dye products. In 1883 he published a paper in which he
described the nucleus of methylene blue and its synthesis; the nucleus he described was
phenothiazine. The identification of and synthesis of methylene blue would have effects far beyond
the dye industry (Swazey, 1974).
The advent of CZP in 1950 was the result of the combination of two lines of research. One
line was concerned with the production of synthetic antihistamines that were powerful and nontoxic
enough to be used in the treatment of allergies. The other was phenothiazine chemistry that was
aimed at creating drugs that could be used to fight malaria, African sleeping sickness, and worm
infestations. In 1945, these lines of research merged when chemists at the French laboratory
Rhone-Poulenc discovered that a phenothiazine amine compound named 3015 RP, synthesized by
Paul Charpentier, had strong antihistamine properties (Swazey, 1974). Research into phenothiazine
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amines was further advanced in 1946 when it was reported to be useful in the treatment of
Parkinson’s disease. These clinical effects of the phenothiazine amine, namely sedation, led
researchers to believe that these drugs had some type of unknown central nervous system effects.
Concurrent with the research being conducted at Rhone-Poulenc, French navy surgeon
Henri Laborit was using synthetic antihistamines to fight circulatory shock after surgery. While
using antihistamines, Laborit noted secondary qualities beneficial to the prevention and treatment of
surgical shock: hypothermic and gangliopalegic properties. This, coupled with other clinical findings
were factors in Rhone-Poulenc’s decision to begin research into the development of a phenothiazine
amine that displayed a high degree of central nervous system activity regardless of it antihistaminic
activity (Koetschet, 1955). In 1950, Rhone-Poulenc began intensive studies of CPZ’s
pharmacological properties; the results of these initial studies indicated strong central action and
clinical trials.
Laborit, who wanted an alternative to the drug he was using at the time, began using CPZ to
relax patients and reduce the likeliness of surgical complications and shock. He reported that
patients who received 50-100 mg intravenously had some drowsiness but were indifferent to the
surgical procedure; in fact, he reported that his patients had a broader indifference and seemed not
to care about anything at all (Laborit, Huguenard, & Alluaume, 1952). Labroit’s results led him to
suggest to a number of psychiatrists that the use it with psychiatric patients. However, not many of
his colleagues were interested.
CPZ’s efficacy as an antipsychotic was not clinically established until 1952. Until this time, a
small series of publications had been reporting the use of CPZ in French psychiatric patients, with
some success. These papers showed that CPZ was being used in four major ways: 1) as a barbiturate
potentiator in manic agitation; 2) in conjunction with shock treatment in anxiety states and manic
depressive states; 3) the potentiation of other drugs in sleep therapy; and 4) administered alone. It
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was this last area of research, used alone, that is historically the most significant (Swazey, 1974). In
1952, John Delay and Pierre Deniker presented a report to the Societe Medico-Psychologique that,
while not a permanent cure, CPZ was effective in reducing manic states in psychiatric patients
(Delay & Deniker, 1952). This report is often cited as being the first public presentation of an
effective drug treatment for a mental disorder (Marder & Van Putten, 1995).
News of this discovery spread quickly, and within two years CPZ was used around the world
to help individuals with agitation associated with mania and nausea. CPZ’s rapid and widespread
increase in usage can be attributed to several factors. The foremost of which was that until CPZ,
there was no other effective treatment for schizophrenia or any other form of psychosis (Marder &
Van Putten, 1995). Another factor was that CPZ was inexpensive to administer and was considered
relatively safe, despite it side effects. Further, CPZ was effective for a large number of individuals,
leading to a decrease in the use of restraint devices, seclusion, and locked units. Unfortunately,
many individuals have residual symptoms and continue to relapse.
However, the advent of CPZ for use in psychiatric populations was not the only
precipitating factor to spark research into the biological basis of psychotic disorders and drug that
could be used to treat them. Several decades’ earlier, Indian researchers began scientific
investigations of R. serpentina, a tropical species of shrub that grows in regions of India. In the
early 1930’s, researchers isolated several of R. serpentina’s alkaloids and began documenting their
physiological activity and noted that the compound was useful in treating violent manic symptoms
associated with insanity (Baumeister & Francis, 2002). Shortly after the publication of these results,
Ciba laboratories identified the sedative aspect of R. serpentina, which they named reserpine and
marketed as an antihypertensive-sedative called Serpasil. (Baumeister, Hawkins, & Uzelac, 2003).
Clinical trials soon established that the clinical profile of reserpine was close to that of CPZ, that is,
both drugs were sedating without producing a clouding of consciousness as found in barbiturates
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(Swazey, 1974). These new drugs were labeled neuroleptics, a term arising from the Greek works
neuron and leptos meaning to “take hold of the nervous system” (Deniker, 1983).
While the discovery of CPZ was paramount in the beginning stages of psychopharmacology
and neuroleptic drug development, it was not a cure all and not without problems. Shortly after
CPZ’s introduction in 1952, side effects that included induced Parkinsonism and other
extrapyramidal side effects (EPS), such as tardive dyskinesia, were being reported (Lehmann &
Hanrahan, 1954). The ability of neuroleptic drugs to produce antipsychotic as well as extrapyramidal
effects has been attributed to their ability to block the D2 dopamine receptor subtype. Because
typical antipsychotics often do not result in a full remission of symptoms and produce unwanted
side effects, researchers have been searching for better antipsychotic drugs. Researchers have been
focusing on compounds with an improved efficacy on both positive symptoms (an excess or
distortion of normal functioning such as delusions, hallucinations, and disorganized speech) and
negative symptoms (restrictions in the range and intensity of emotional expression, fluency and
productivity of speech and thought, and initiation of goal oriented behavior) and side effects profiles
(APA, 2000; Owens & Risch, 1995).
Second-generation antipsychotics have been termed atypical, as they tend to produce fewer
extrapyramidal side effects and improved efficacy at therapeutic doses (Owens & Risch, 1995).
While unclear, the mechanism of action of the atypical drugs is considered to be through either
differential actions in various dopamine neurons and/or binding to different dopamine receptor
subtypes, or additional binding to other neurotransmitter receptors (Owens & Risch, 1995). Studies
have shown atypical drugs to be relatively weaker D2 antagonists and that they possess relative
mesolimbic dopaminergic specificity compared to nigrostriatal dopamine neurons. This selective
targeting may explain why atypical antipsychotics have fewer EPS side effects and tardive dyskinesia
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liability. Six second-generation atypical antipsychotic medications have been introduced since the
late 1980’s and include olanzapine, risperidone, sertindole, and ziprasidone.
Clinically, neuroleptics are generally effective in controlling psychomotor agitation and
excitement, in the management of psychosis, and the treatment of schizophrenia and mania
(Lieberman & Mendelowitz, 2000). Antidepressants are useful in the treatment of depressive
disorders and anxiety disorders such as obsessive-compulsive and panic disorders (Ban, 2001).
Minor tranquilizers relieve tension and are used to treat panic attacks and generalized anxiety
disorder, and hypnotics-sedatives are used in the treatment of insomnia (Diamond, 2002). Mood
stabilizers are used to treat manic-depressive and bipolar disorders (Hopkins & Gelenberg, 2000).
Stimulant medications are used to treat attention deficit hyperactivity disorder and narcolepsy
(Fawcett & Busch, 1995). Cholinesterase inhibitors have shown promise in the treatment of
Alzheimer’s disease (Ban, 2001).
Determining which medication is best suited for an individual is a complex task. To aide
clinicians in this task, several expert consensus guidelines have been developed (Rush & Frances,
2000; Reiss & Aman, 1998), along with medication algorithms such as the Texas Medication
Algorithm Project (Gilbert et al., 1998; Rago & Shon, 2001). These guidelines and algorithms
provide clinicians with step-by-step procedures for the implementation of medication regimens
based on the characteristics of an individual and their presenting symptomology. In addition, they
provide clinicians with alternative drug therapies if the first line does not have a significant positive
impact. Therefore, these guidelines also serve to inform clinicians about the multiple uses and
combinations of various medications to safely reach a desired therapeutic effect and how to
effectively monitor their clients progression. The following is a review of the most common classes
of medications shown to be useful among individuals with mental retardation including drug
mechanisms, clinical effects, and side effects.
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Antipsychotic Medications
Antipsychotic drugs are used to treat nearly all forms of psychosis and psychoses associated
with organic mental disorders (Marder & Van Putten, 1995). First generation antipsychotics are
classified as a neuroleptic; a term arising from the Greek works neuron and leptos, meaning to “take
hold of the nervous system” and used to describe the adverse motor slowing effects of these drugs
(Lieberman & Mendelowitz, 2000). The implication was that the motor side effects were a
fundamental part of the therapeutic aspects of the drugs and could not be separated out. Thus,
typical antipsychotic drugs developed until the late 1980’s were considered to be neuroleptics.
However with the introduction of clozapine, the first of the second-generation medications to have
antipsychotic properties without EPS, the term neuroleptic was no longer appropriate (Lieberman &
Mendelowitz, 2000). As such, second-generation neuroleptics were termed atypical antipsychotics.
Although drug classes are based on biochemical structure, a more meaningful classification within
antipsychotic medications is whether they are EPS-producing neuroleptics or non-EPS-producing
antipsychotics (Stahl, 1996).
Mechanism
The traditional, or older, typical antipsychotic medications typically exerted their effects by
blocking the D2 dopamine receptor in the brain. There are four major dopamine pathways in the
brain and typical antipsychotics block all four of these pathways. However, the dopamine pathway
located in the limbic system, specifically the mesolimbic dopamine pathway is considered
responsible for psychotic symptoms. Generally, chemicals that decrease activity in this pathway
decrease psychotic symptoms while chemicals that increase activity increase, or cause, psychotic
symptoms (Diamond, 2002). Another dopamine pathway located in the frontal cortex that
stimulates behavior, thought, expression, and motivation is the mesocortical dopamine pathway.
Blocking dopamine in this pathway decreases these aspects of an individual’s personality and can
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exacerbate the negative symptoms of schizophrenia. The third dopamine pathway is located in the
nigrostrital pathway, an area responsible for the control of the extrapyramidal motor system.
Blocking dopamine in this pathway causes a loss in voluntary muscle movement resulting in
parkinsonism-like extrapyramidal side effects (EPS) (Stahl, 1996). The fourth pathway is the
tuberoinfundibular dopamine pathway responsible for the secretion of prolactin, a sex-related
hormone produced by the hypothalamus. When this pathway is blocked, the individual’s prolactin
level increases and can result in breast enlargement, secretion of a milk-like substance from the
breasts in both men and women, and other sexual side effects. As the typical antipsychotics are not
selective with respect to which pathway dopamine is blocked.
New atypical antipsychotic medications leave dopamine receptors in other parts of the brain
largely unaffected by using the brain’s own self-regulation system (Diamond, 2002). One hypothesis
is that serotonin blocks the release of dopamine in some brain pathways. As such, blocking
serotonin receptors causes nerve cells to release more dopamine. If both serotonin and dopamine
receptors are blocked at the same time, the result is a net increase in the amount of dopamine
released. However, as only some of the dopamine receptors are blocked, the dopamine system is
less sensitive to the increased amount of dopamine and the overall response to dopamine remains
about the same. Thus, the increased amount of dopamine released has relatively no effect in those
areas that have a serotonin control system. Interestingly, there is no serotonin control system in the
mesolimbic dopamine pathway, the pathway responsible for the expression of psychotic symptoms.
By blocking dopamine and serotonin at the same time, atypical antipsychotic medications selectively
block dopamine in only one part of the brain. However, reaching a balance between blocking
serotonin and dopamine is not easy and there is more than one type of serotonin receptor.
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Side Effects
All antipsychotic medication side effect profiles can be grouped into four broad categories:
1) muscle related, or extrapyramidal, 2) non-muscle related, 3) dangerous or rare, and 4) weight gain
and diabetes. These categories represent a wide range of potential side effects that correspond to
each drugs pharmacological properties (Lieberman & Mendelowitz, 2000). Further, typical and
atypical antipsychotic medications vary widely in their side effect profiles both between and within
each drug classification.
All of the typical antipsychotic medications reduce psychotic symptoms by blocking
dopamine receptor sites in the brain. However, each of the typical antipsychotic medications varies
in potency. That is, different amounts of each medication are required to be equally effective. High
potency medications are relatively less sedating, cause less postural hypotension, and cause fewer
anticholinergic side effects such as blurred vision, constipation or dry mouth (Stahl, 1996).
However, high potency typical antipsychotic medications also have a higher incidence of
extrapyramidal side effects (EPS) such as tremors, motor restlessness, and tardive dyskinesia. New
atypical antipsychotic medications also produce extrapyramidal side effects but with far less
incidence and severity than the typical antipsychotic medications.
The first category of side effects is extrapyramidal effects. Pyramidal nerve cells are those
cells in the brain that control voluntary muscle movement. Extrapyramidal refers to those areas in
the central nervous system that are not part of the main pyramidal tract and are concerned with
control and coordination of muscle movements. While not typically dangerous, this category of side
effect is uncomfortable and cause many individuals to discontinue the use of their antipsychotic
medication. Most of the EPS’s, with the exception of tardive dyskinesia and akathisia, are usually
treatable with other medications such as anticholinergic agents and disappear with the
discontinuation of the antipsychotic medication. Each EPS has a time course, except for tardive
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dyskinesia) and may not require medication treatment. Tardive dyskinesia, a set of hyperkinetic
movements that especially effects the face, neck, and extremities and can include movements such as
lip smacking, chewing, tongue protrusions, facial grimacing, and rapid limb movements has no
reliable treatment and persist even after antipsychotic medication is stopped. Other EPS’s include
dystonia; sudden spasms of the muscles in the head, neck, lips, and tongue; pseudoparkinsonism,
which consists of muscular rigidity, mask-like face, and a stiff walk; akathisia, characterized by
constant pacing, moving of hands and feet, and a feeling of nervousness; and akinesia, manifested by
a loss of spontaneity in facial expression or gesturing, decreased social spontaneity, diminished
conversation, apathy, and disinclination to initiate normal activity.
Common, non-muscle related effects are a second broad category of side effects seen in
antipsychotic medications. This category includes effects such as, depression, depersonalization,
akinesia, confusion, somatic delusion, and dysphoria. These side effects are seen more in the typical
antidepressants (Diamond, 2002). Anticholinergic side effects such as dry mouth, blurred vision,
and constipation are also included in this category. As anticholinergic medications block the
sweating response, temperature regulation problems are another common set of side effects. Most
of the anticholinergic side effects seen actually come from the medications used to treat the muscle
related side effects of the antipsychotic medications, such as cogentin, donepezil, galantamine, and
rivastigmine (Tammenmaa, McGrath, Sailas, & Soares-Weiser, 2004). Another set of non-muscle
related side effects are alpha-adrenergic. These include orthostatic hypotension, a sudden drop in
blood pressure when an individual stands up and transient dizziness. Again, these side effects are
seen more in typical antipsychotics. However, in atypical medications the effects are worse with
clozapine and risperidone. As antipsychotic medications block the D2 receptor they cause an
increase in prolactin, again seen more with typical antipsychotic medications. This can result in
breast enlargement, secretion of breast liquid from men and women, interference with menstrual
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periods in women, and a decreased sex drive. Photosensitivity is another side effect caused by
antipsychotic medications.
Antidepressant Medications
The discovery of the antipsychotic properties of chlorpromazine began the revolution in the
pharmacological treatment of psychosis. Similarly, the accidental discovery of the antidepressant
properties of the antituberculosis drug iproniazid revolutionized the treatment of depression in the
1950’s (Mendelowitz, Dawkins, & Lieberman, 2000). Until this time no effective antidepressants
existed. In the early 1950’s it was noted that a side effect of iproniazid was euphoria. This
observation led to clinical trials during which it was discovered that iproniazid was useful for
tuberculosis patients with depression (Crane, 1957). Another accidentally discovered antidepressant
was imipramine, which was originally developed as a potential antipsychotic. However, during
clinical trials it was noted that imipramine elevated mood in individuals with schizophrenia. This
discovery led to effective trials with individuals with depression (Kuhn, 1958). Both of these
medications have different mechanisms of action. Iproniazid’s therapeutic efficacy involves the
inhibition of the enzymes that degraded monoamines, which in turn increase norepinephrine,
serotonin and dopamine activity. However, Imipramine’s mechanism of action involves blocking
the reuptake of serotonin and norepinephrine. Thus, there are at least two neurotransmitters
responsible for depression: serotonin and norepinephrine. However, it is not fully understood how
antidepressant medications work. What is known is that all effective antidepressants interact with
one or more neurotransmitter receptors or enzymes (Stahl, 1996).
Mechanism
The theoretical mechanism of action of antidepressant medications involves the serotonergic
and catecholaminergic systems in the central nervous system (Mendelowitz et al., 2000). There are
four classes of antidepressant medications: (1) the monoamine oxidase inhibitors (MAOIs), (2)
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tricyclic antidepressants (TCAs), (3) selective serotonin reuptake inhibitors (SSRIs) and (4)
serotonin-norepinephrine reuptake inhibitors (SNRIs).
The first clinically effective antidepressants were drugs that inhibited the monoamine oxidase
enzyme and were accidentally discovered while researchers were searching for an antituberculosis
drug. When the antituberculosis drug was given to tuberculosis patients the drug was observed to
help their depressive symptoms. As is had already been discovered that the antituberculosis drug
inhibited the monoamine oxidase (MAO) enzyme, it was hypothesized that this biological event
accounted for the drugs antidepressant effects. The MAO enzyme is responsible for breaking down
monoamine neurotransmitters such as dopamine, serotonin, and norepinephrine thereby
functionally decreasing the levels of these neurotransmitters (Janicak et al., 1993). All of the original
MAOIs are irreversible enzyme inhibitors that bind to, and destroy, the monoamines in the
cytoplasm. The effects of the MAOIs continue for 10 to 14 days after their used has been
discontinued, until new MAO enzymes can be synthesized. MAOIs are beneficial in the treatment
and management of atypical depression, mixed anxiety and depressive disorders.
MAO has two subtypes, A and B. Subtype A metabolizes serotonin and norepinephrine, the
monoamine neurotransmitters most closely linked to depression (Stahl, 1996). The subtype B
enzyme is believed to metabolize dopamine and phenylethlamine into toxins that may damage
neurons. Inhibiting the B form of MAO is linked to the prevention of some neurodegenerative
processes such as those found in Parkinson’s. All of the original MAOIs inhibited both of these
subtypes and were therefore nonselective. However, in recent years, new MAOIs have been
produced that selectively inhibit MAO A or MAO B. Further, for MAO A’s, the new drugs are
reversible and are therefore called reversible inhibitors of MAO A (RIMAs). A new RIMA,
Moclobemide, is now available in Canada and the United Kingdom. However, is not yet in the
United States (Mendelowitz et al., 2000).
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Tricyclic antidepressant (TCAs) medications are so named because of their organic threering molecular structure. The results of clinical trials were disappointing and TCAs were almost
discarded. However, researchers noted that TCAs helped relieve some of the depressive symptoms
in patients with schizophrenia who had comorbid depression. It was not until later that researchers
discovered TCAs worked by blocking the presynaptic reuptake of norepinephrine and serotonin,
and, to some degree, dopamine. In addition to these effects, to some degree all TCAs block
muscarinic cholinergic, H1 histamine, and alpha 1 adrenergic receptors (Stahl, 1996). The
therapeutic antidepressant effects of TCAs are thought to be due to the blockage of serotonin and
norepinephrine reuptake, while the blockade of these other three-receptor systems are responsible
for the TCAs side effects.
TCAs modulate the reuptake of neurotransmitters to various degrees. Older TCAs, such as
imipramine and amitriptyline, the tertiary amines, are metabolized into secondary amines by hepatic
enzymes. The tertiary amine TCAs have a greater effect at blocking the reuptake of serotonin than
do the secondary amines which are more effective at blocking the reuptake of norepinephrine.
More importantly, these TCAs have differing clinical effects. Secondary amine TCAs are less likely
to interact with other receptors, as such, the side effect profiles of the secondary amines are
improved over the tertiary amines. All TCAs are considered to be nonselective in that each blocks
the reuptake of monoamines. However, they also interact with a wide variety of other
neurotransmitter receptor systems (Mendelowitz et al., 2000).
The second generation of antidepressant medications selectively blocks the reuptake of one
neurotransmitter receptor system, usually serotonin. This new generation of antidepressants is
known as selective serotonin reuptake inhibitors (SSRIs) as they effectively block the reuptake of
serotonin while having little effect on adrenergic, histaminergic, or cholinergic receptor systems.
Functionally, all SSRIs increase the amount of serotonin available in the synapse. Increased
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serotonin at receptor sites has, for some individuals, the therapeutic effect of relieving some of the
symptoms of depression.
One of the newest second-generation antidepressant medications being developed are
serotonin-norepinephrine reuptake inhibitors (SNRIs). SNRI drugs, such as venlafaxine, share the
inhibitory reuptake properties of the classical TCAs. However, they do not effect the adrenergic,
histaminergic, or cholinergic receptor systems and thus have different therapeutic and side effect
profiles. The blocking properties of venlafaxine are dose dependant; it is most effective in blocking
serotonin and at low doses, norepinephrine at higher doses, and dopamine at the highest doses.
Although SNRIs are clinically effective as antidepressants, it remains unclear whether or not they
have advantages over SSRIs in terms of efficacy or side effect profile (Stahl, 1996).
Side Effects
The use of MAOIs in the United States has begun to decline in recent years. This is
primarily due to the need for dietary restrictions and the potential for serious side effects
(Mendelowitz et al., 2000). The most common long-term side effects of MAOIs are weight gain,
edema, muscle twitching, and decreased sexual functioning. Other side effects of MAOIs include
anticholinergic effects such as blurred vision, dry mouth, urinary hesitancy, constipation, behavioral
problems, and memory impairment. A less common but more serious side effect of MAOIs is a
hypertensive crisis caused by the interaction of the MAOI with tyramine found in food or a
medication that contains a sympathomimetic amine, amines that have an effect on the sympathetic
nervous system. MAOIs work by interfering with the enzymes that break down neurotransmitters.
However, some of these enzymes also break down tyramine. Therefore, tyramine levels can increase
to high levels and cause an increase in blood pressure. The hypertensive crisis is usually preceded by
a sudden increase in blood pressure, headache, stiff neck, and vomiting (Maxmen & Ward, 2002).
While rare, the hypertensive crisis may be fatal and requires immediate treatment. Besides a wide
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range of foods, MAOIs also interact with a large number of medications, including many over-thecounter medications and other antidepressants. Further, MAOIs have an activating effect that may
result in manic episodes, psychosis, behavioral outbursts, loss of sleep, and decreased attention.
NDRIs are effective antidepressants and are reported to have fewer side effects than the
older antidepressant medications, because they do not affect serotonin systems. One of the major
advantages of NDRIs is that they do not cause any sexual side effects; in fact, it can actually reverse
the sexual side effects of other antidepressant medications (Diamond, 2002). As with MAOIs,
NDRIs are also activating and thus cause side effects such as restlessness and sleep problems.
However, the occurrence of these side effects is less than with MAOIs. Rare side effects of NDRIs
include nausea and slight tremors. Unfortunately, NDRIs have an increased risk of grand mal
seizure than most other antidepressants (Stahl, 1996). This risk is dose related and increases as the
dosage of the NDRI increases.
Tricyclic antidepressant medications, although older, are just as clinically effective as the new
antidepressant medications. However, the major problem is that TCAs are much more dangerous
especially when taken as an overdose; a month’s worth of any TCA is lethal if taken all at once.
Individuals taking TCAs typically feel drugged and sedated more than with the newer
antidepressants. As TCAs block the muscarinic cholinergic, H1 histamine, and alpha 1 adrenergic
receptors, they have many more side effects that most of the newer, selective antidepressant
medications (Mendelowitz et al., 2000). The anticholinergic properties of TCAs cause side effects
such as dry mouth, blurred vision, heart palpitations, urinary retention, confusion, and delirium
while blockage of the histamine receptors causes sedation and weight gain. Blocking the adrenergic
receptors creates one of the TCAs most frequent and limiting side effects, orthostatic hypotension,
the sudden loss of blood pressure, and cardiac arrhythmias due to the inability of electrical impulses
in the heart to spread normally (Diamond, 2002). While rare, these cardiac complications have been
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reported to cause death. TCAs also potentiate the effects of alcohol and individuals who drink while
on TCAs may become more intoxicated than usual. Further, TCAs increase the lethality of alcohol
and put the individual at risk for overdose. Other side effects of TCAs are loss of sexual function,
manic episodes, allergies, nightmares and seizures.
The advantage of the SSRIs is that they are much safer and better tolerated than the older
antidepressant medications. This is because the SSRIs only selectively inhibit the reuptake of
serotonin and have little, if any, interaction with histaminergic, muscarinic, or alpha-adrenergic
receptors. Thus, the side effect profiles seen in the SSRIs are caused by the blockage of serotonin
reuptake. As such, while not significantly more effective than older and other antidepressants,
SSRIs are becoming more widely used because of the fewer side effects they cause. Some of the
common side effects caused by SSRIs are nausea, vomiting, anorexia, tremors, initial weight gain,
and diarrhea. However, most of these are dose dependent and can be lessened by titrating the
medication more slowly and having the individual take the medication with food (Mendelowitz et al.,
2000). Like some of the other antidepressants discussed earlier, SSRIs tend to be activating, thus
some individuals feel agitation, restlessness, and some sleep disturbance. Further, some SSRIs such
as fluoxetine (Prozac) cause akathisia, a type of motor restlessness. Also, some individuals feel an
emotional blunting. Although most antidepressants cause some degree of sexual dysfunction, the
incidence of sexual dysfunction in SSRIs is more common (Janicak et al., 1993). These side effects
include decreased libido, anorgasmia in women and delayed ejaculation in men.
SSRIs also interact with other medications in dangerous ways by blocking their metabolism
in the liver (Diamond, 2002). By blocking the break down of other drugs, SSRIs can cause the levels
of other medications to rise to toxic levels. Specifically, SSRIs interfere with a set of enzymes in the
liver called the P450 system. To complicate matters, different SSRIs interfere with different
enzymes in the P450 system, thus different SSRIs interact with different medications to cause
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different problems. SSRIs also interact with many medications used to treat HIV. Research shows
that individuals taking HIV medication should only be prescribed ¼ to ½ of the normal dose
(Diamond, 2002). The most dangerous and common interaction between SSRIs and other
medications occur when the individuals is also taking an MAOI antidepressant. This combination,
the SSRI and an MAOI, can result in serotonin syndrome whose symptoms include agitation,
confusion, sweating, increased reflexes, sudden jerking movements, shivering, tremors, coordination
problems, and fever.
Mood-Stabilizing Medications
The discovery of medications that could stabilize an individual’s mood dates back to the late
1940’s. The first drug used as an anti-manic was lithium that had been used in medicine since the
mid-19th century to treat a variety of disorders such as diabetes, gout, rheumatism, and urinary
calculi. During the early 1940’s it was used as a salt substitute for cardiac patients. However, lithium
caused a number of toxic reactions and deaths (Janicak et al., 1993). Then in late 1949, John Cade,
an Australian physician injected lithium urate into guinea pigs. Cade mistakenly took the toxic
effects of lithium as sedating and, based on this, ran a successful open trial of lithium with manic
patients. In 1954, Mogens Schou used lithium in a series of methodologically rigorous studies that
demonstrated its efficacy in stabilizing both phases of bipolar disorder and preventing recurrences of
unipolar depressive disorder in patients (Schou, Juel-Neilson, Stromgren, & Voldby, 1954). After
lithium’s anti-manic properties were discovered, a series of studies were conducted that replicated
Cade’s initial findings. While these studies demonstrated lithium’s usefulness, they also revealed that
lithium was still toxic and lethal when used as an anti-manic. It was not until the 1960’s when
Samuel Gershon reintroduced lithium as a viable treatment for mania that it became the standard
therapy for bipolar disorder and was approved for use in the United States in 1970 (Hopkins &
Gelenberg, 2000).
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However, recent research has begun to acknowledge that a significant proportion of patients
cannot tolerate or do not benefit from lithium therapy (Janicak et al., 1993). Individuals who do not
seem to respond to lithium include those that present with dysphoric and mixed episodes of mania,
rapid cycling, a history of neurological disease, and comorbid substance abuse (Hopkins &
Gelenberg, 2000). This has led to investigations into alternative treatments such as
electroconvulsive therapy (ECT) and antiepileptics. The most common antiepileptics used to treat
mania in patients that are unresponsive to lithium are valproate (VPA) and carbamazepine (CBZ).
As with most of the other psychotropics, the anti-manic properties of antiepileptic medications,
specifically CBZ, were discovered by accident. In the 1960s, researchers were studying the effects of
CBZ in epileptic patients and noted that it also had anti-aggressive properties (Dehing, 1968). While
VPA is approved for the acute care of mania, this section will focus on the mechanism and side
effects of lithium as used as a mood stabilizer. VPA and CBZ will be discussed further in the
antiepileptic section along with other antiepileptic medications that are currently being researched
for their anti-manic properties.
Mechanism
While many of lithium’s effects on the body are known, the exact mechanism that is
responsible for its mood stabilizing properties are not fully understood, although several theories
have been postulated (Viesselman, 1999). One theory is that it affects those neurotransmitter
systems implicated in affective disorders, norepinephrine, acetylcholine, serotonin, and dopamine.
Lithium has a variable effect on norepinephrine by inhibiting its release and seems to enhance
acetylcholine function. Its antidepressant effects may be due to its enhancement of serotonin
activity and its anti-manic properties are thought to be due to its prevention of dopamine receptor
super sensitivity and inhibition of its release (Hopkins & Gelenberg, 2000).
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Another theory is that lithium affects cellular processes, specifically affecting secondmessenger G-protein systems and signal-transduction systems. A third theory is that lithium alters
neuron functioning by substituting or competing with other ions, as it shares properties with
potassium, sodium, magnesium, and calcium, and altering their distribution throughout the body. A
fourth theory is that lithium may modulate the interaction between several neurotransmitters and act
as a neuromodulator and balance various neurotransmitter systems. Research continues to
determine the exact nature of lithium’s therapeutic effects as a mood stabilizer.
Side Effects
Lithium produces a wide variety of side effects, some of which the individual may become
tolerant of and others that may warrant the use of adjunctive or alternative therapies. The most
common side effect of lithium is fine tremor of the hands during the first few days of treatment
(Stahl, 1996). Other initial side effects of lithium are nausea, vomiting, abdominal pain, thirst, and
fatigue. However, most of these disappear after the first few weeks of treatment. Other reported
side effects include mild weight gain, a metallic taste in the mouth, headache, memory and
concentration difficulties, dermatitis, and polyuria (Maxmen & Ward, 2002). Lithium is also known
to affect thyroid function by inhibiting several steps of thyroid hormone synthesis and degradation
resulting in hypothyroidism. As the kidney excretes lithium, it also has a direct effect on renal
functioning and may cause a syndrome called nephrogenic diabetes insipides characterized by
increased fluid intake and urination. However, very few individuals who receive long-term lithium
therapy suffer permanent, life-threatening kidney damage. Lithium has a low therapeutic index, and
increased blood concentrations can cause eventual coma or death (Stahl, 1996). The initial
symptoms of lithium toxicity look like more severe presentations of common lithium side effects
such as thirst, decreased appetite, diarrhea, and vomiting. These symptoms can progress to tremors,
confusion, slurred speech, and muscle twitching. If left untreated, the toxic lithium blood levels can
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cause permanent central nervous system damage, increased reflexes, renal shutdown, seizures,
permanent brain damage, coma, and possible death.
Antianxiety Medications
The discovery of antianxiety medications, also known as anxiolytics, did not have an
accidental beginning like most other psychotropics. The use of anxiolytics can be traced back
centuries to alcohol and its progression can be followed from there to the use of opiates to the
synthesis of bromides and barbiturates to the formulation of benzodiazepines in the 1960s (Janicak
et al., 1993). All of these medications have similar affects; they all have antianxiety and sedative
properties caused by depression of the central nervous system. The earliest treatment for general
anxiety was barbiturates, which were highly sedating. In fact, the antianxiety effect of barbiturates
was directly proportional to its sedating affect, thus its effects were not anxiety specific. That is,
these drugs reduced anxiety by inducing sedation. Also, this class of antianxiety medication had
some serious problems such as dependency and withdrawal effects, and safety concerns when
combined with other medications or in overdose. Barbiturates were supplanted when
benzodiazepines, a new class of antianxiety medication, were discovered. These new drugs had
fewer problems, were effective in a wider range or disorders, safe with most other medications, and
caused less sedative effects than barbiturates (Diamond, 2002). For the first time, selective
antianxiety effects were observed. Benzodiazepines were hailed as a breakthrough and remain
among the most widely prescribed drugs in the world. Recently, a new class of anxiolytic drug has
been formulated called azapirones that are not chemically related to barbiturates or benzodiazepines
and affects different neurotransmitter systems. Currently, buspirone is the only azapirone indicated
for the treatment of anxiety. This section will focus on benzodiazepines and the newer anti-anxiety
medication, buspirone.
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Mechanism
All benzodiazepines are comprised of a 6-member benzene ring fused to a 7-member
diazepine ring, and thus get their name from their chemical structure. The different
pharmacokinetic properties seen within benzodiazepines results from different substitutions on the
diazepine ring in different positions; therefore, each structure differs in potency, duration of action,
and the type and frequency of side effects (Janicak et al., 1993). The wide diversity in therapeutic
and side effect profiles of the different benzodiazepines is due to the speed of onset of action,
potency, and the half-life of the specific medication. These factors allow for the selection of specific
medications to fit the needs of the individual. However, as all benzodiazepines have the same basic
chemical structure, they all share four principal therapeutic actions to some extent: anxiolytic,
myorelaxant (muscle relaxant), anticonvulsive, and sedative-hypnotic (Fogelman & Greenblatt,
2000).
Benzodiazepines produce their antianxiety effect by potentiating the neurotransmitter
gamma-aminobutyric acid (GABA), the major inhibitory neurotransmitter in the central nervous
system that acts in the cortex, substantia nigra, and in the cerebellum. GABA receptor complexes
can be divided into two physiologically and pharmacologically distinct subtypes that regulate GABA
neurotransmission, GABAA and GABAB. The GABAB receptor subtype is not modulated by
benzodiazepines and its physiological role is not well known. However, it appears that GABAB may
not be linked to anxiety disorders or the effects of anxiolytic medications (Janicak et al., 1993).
GABAA receptors are, on the other hand, indicated in anxiety disorders and the therapeutic effects
of benzodiazepines.
Three subtypes of benzodiazepine receptors exist. Type 1 receptors, also known as omega-1
receptors, are located preferentially in the cerebellum and amygdala and seem to be responsible for
the anxiolytic and sedative responses to benzodiazepines. Type 2 benzodiazepine receptors, also
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known as omega-2, are located primarily in the spinal cord and striatum. As such, these receptors
may be responsible for mediating the muscle relaxant effects of benzodiazepines. The last type of
benzodiazepine receptor, type 3 or omega-3, is located primarily in the peripheral nervous system
and its role concerning the mediation of the anxiolytic effect of benzodiazepines is unclear (Stahl,
1996).
In effect, benzodiazepines facilitate GABA-mediated transmission and thus act as an indirect
GABAA agonist by enhancing the receptor site affinity of GABA and potentiating its inhibitory
action. When benzodiazepines bind to the receptor site, a conformational change takes place and
the subunit’s affinity for GABA increases. This increases the probability of GABA binding to its
receptor site and a net increase in the frequency chloride channel opening, movement of chloride
into the neuron, and hyperpolarization of the cell. If GABA is not present in the synapse,
benzodiazepines have no pharmacological action. Only when GABA and the benzodiazepine are
present does the interaction between the medication and the GABA receptor complex promote the
anxiolytic therapeutic effects of benzodiazepines.
A new class of anxiolytics not chemically related to benzodiazepines recently developed is
azapirone. Buspirone is the first medication from this class that has been approved for the
treatment of anxiety. The therapeutic profile of buspirone, or buspar, is quite different from the
benzodiazepines in that it has no effect on the GABA receptors. Instead, buspar seems to act
primarily at serotonin and dopamine receptor sites. As such, it does not have the sedative,
myorelaxant, or anticonvulsive properties seen in benzodiazepines. While the exact anxiolytic
mechanism of buspar remains unknown, it appears that buspar act as a partial serotonin agonist at
postsynaptic receptors and a full agonist at presynaptic receptors (Werry & Aman, 1999). Thus,
buspar seems to regulate serotonin systems and return their functioning to normal levels (Fogelman
& Greenblatt, 2000). For example, in conditions of serotonin deficiency, buspar’s overall effect is to
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increase serotonergic activity. Currently there are several other azapirones that are being tested for
their anxiolytic properties; these include drugs such as gepirone, tandospirone, and ipsapirone.
While promising, some question has arisen as to their efficacy in treating certain anxiety related
disorders and their overall effectiveness when compared to benzodiazepines.
Side Effects
While the side effects of benzodiazepines are broad, they are generally well tolerated and
dose dependant. The most common side effects are drowsiness, sedation, anterograde amnesia,
impaired psychomotor performance, and ataxia. The degree of these side effects is, again, related to
dose and also the particular subgroup of benzodiazepine being used (Maxmen & Ward, 2002). A
major concern with this class of medication is its addictive properties. Those benzodiazepines with
rapid onset, such as Valium, are much more likely to cause dependence than those with slow onset,
such as Librium. However, all benzodiazepines have addictive properties and may also cause
sweating, nausea, disinhibition, hyperactivity, irritability, and aggressiveness along with a rebound of
the initial symptoms after discontinuation. Another concern with the use of benzodiazepines is
memory impairment and impairment of other cognitive functions. These effects are particularly
applicable to the elderly, and individuals with memory impairment, mental retardation or
developmental disabilities.
A major advantage of buspar is its lack of abuse potential. Also, buspar is non-sedating,
does not increase an individual’s sensitivity to alcohol, and is not a myorelaxant. Some common
side effects include nervousness, dizziness, headache, and some gastrointestinal upsetting. It appears
that buspar’s side effect profile is significantly less than those of the benzodiazepines. However,
there are some factors that may limit buspar use with some individuals. One factor is its delayed
onset of action. While some benzodiazepines work almost immediately, buspar may take several
weeks to exert its full therapeutic effect and it must be used regularly during this time. Another
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factor is its effectiveness across a range of anxiety disorders. As a wide array of benzodiazepines
exists, a specific medication can be selected to fit the individual and their symptom presentation; the
same is not true for buspar. Individuals who have not previously used a benzodiazepine report that
buspar is very effective in controlling their anxiety while individuals who previously used a
benzodiazepine reported that buspar was not as effective as their previous medication (Diamond,
2002). Research suggests that buspar may be particularly useful for individuals who may be drug
users and cannot tolerate the various cognitive side effects of the benzodiazepines.
Antiepileptic Medications
Although carbamazepine (CBZ) was developed in the late 1950’s, its antiepileptic properties
were not reported until 1963. In the early 1960’s CBZs antiepileptic and psychotropic effects began
to appear in the research literature (McElroy & Keck, 1995). In 1974 the U.S. Food and Drug
Administration (FDA) approved its use as an antiepileptic for adults; in 1978 the FDA approved
CBZ for use with children, and in 1987 CBZ was approved without an age limitation. Currently,
CBZ is a major antiepileptic medication whose use is increasing due to its relatively few
psychological and neurological toxic side effects. Since the introduction of CBZ, several other
antiepileptic medications have been developed or discovered. However, many of these, such as
phenobarbital and phenytoin are no longer widely used as they have many behavioral and cognitive
side effects, some of which are often irreversible (Iivanainen, 1998; Ingram, 1986).
An alternative antiepileptic being widely used today is valproate, or valproic acid (VPA).
First discovered in 1882 and used as an organic solvent, the discovery of its antiepileptic properties
was serendipitous. VPAs antiepileptic properties were discovered in 1963 in France where VPA was
originally used to deliver other drugs being tested for their antiepileptic properties. Researchers
noted that some compounds, when administered alone, did not have antiepileptic properties.
However, when these compounds were dissolved in VPA they inhibited seizure activity. It was soon
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concluded that VPA was responsible for this observed result. Initial clinical trials concerning VPAs
efficacy as an antiepileptic were conducted in the mid 1960’s and the drug became available in the
United States in 1978. As discussed previously, VPA is also currently approved as a mood
stabilizing medication.
In addition to CBZ and VPA, benzodiazepines are also used as antiepileptic medications,
especially clonazepam and clorazepate. However, while benzodiazepines are considered to be one
of the safest having fewer severe side effects, it does have significant sedative properties (Mycek,
Harvey, & Champe, 1997). Further, its efficacy as an antiepileptic is not well documented and its
role is typically as a therapeutic adjunct. There are a number of newer antiepileptic medications such
as gabapentin, lamotrigine, and vigabatrin that have fewer and less severe side effect profiles
(Bhaumik, Branford, Duggirala, & Ismail, 1997). However, few studies can be found on their
efficacy and use on individuals with mental retardation. As such, this section will be limited to CBZ
and VPA, two of the more current and widely used antiepileptic medications. Although significant
in the development of antiepileptics, phenobarbital and phenytoin will not be discussed in this
section.
Mechanism
Carbamazepine is typically used for the control of both partial and generalized tonic-clonic
seizures and its chemical structure is similar to that of the TCA imipramine. Its actions can be
divided into two mechanisms (MacDonald, 1989). One mechanism involves CBZs effects on
synaptic and postsynaptic neurotransmitter transmission. CBZ has been reported to alter
neurotransmitter concentrations, metabolism, receptors, and second messenger systems (McElroy &
Keck, 1995). It is this mechanism that is believed to be responsible for the mood stabilizing effects
of CBZ. The second mechanism of CBZ involves its effects on neuronal ion channels that reduce
high-frequency repetitive firing of action potentials. Research suggests that this latter mechanism is
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responsible for the antiepileptic properties of CBZ (McElroy & Keck, 1995). Recently, research has
suggested that CBZ also acts on potassium channels to increase potassium conductance (Post,
Weiss, & Chuang, 1992). This may be another possible mechanism explaining the antiepileptic
properties of CBZ.
VPA is useful in controlling a wider variety of seizure types than CBZ including absence,
myoclonic, tonic-clonic, and complex partial seizures (Vining, Carpenter, & Aman, 1999). The exact
mechanism that is responsible for valproate’s antiepileptic properties remains unknown. One theory
is that VPA exerts its therapeutic effects by changing how the neurotransmitter GABA is
metabolized (McElroy & Keck, 1995). VPA seems to inhibit the catabolism of GABA causing an
increase in GABA release, a decrease in GABA turnover, and increases GABAB receptor density.
Another theory is that VPA produces its antiepileptic properties by regulating the intake and
excretion of sodium and potassium (Post, Weiss, & Chuang, 1992). Further research is needed to
determine the exact mechanism responsible for VPA’s antiepileptic properties.
Side Effects
CBZ’s side effect profile is somewhat more favorable than those of lithium, antipsychotics,
and other antiepileptic medications (Smith & Bleck, 1991). Importantly, CBZ rarely causes EPS or
renal side effects, and is associated with fewer cognitive and neurological side effects than previous
antiepileptic medications. Further, CBZ produces less weight gain, hair loss, and tremor than VPA
(Diamond, 2002). However, CBZ does cause increased sedation, has a higher incidence of serious
side effects, and has the potential to be fatal in an overdose. Common neurological side effects
blurred vision, fatigue, nausea, vertigo, and ataxia. These side effects are dose dependent and most
disappear after a few weeks. Some medically dangerous side effects associated with CBZ are
leukopenia, a drop in the number of available white blood cells; temporary increases in liver
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enzymes, and hyponatremia. Rare side effects are liver problems, hepatic failure, exfoliative
dermatitis, pancreatitis, and psychological disturbances such as psychosis and mania.
Generally, the side effects of VPA are well tolerated and provide a viable alternative for
many individuals who cannot take other medications a viable alternative (Diamond, 2002). Research
indicates that there is a low incidence of adverse effects when compared to lithium, antipsychotics,
and other antiepileptics including CBZ (Smith & Bleck, 1991). Further, VPA is less likely to cause
cognitive impairments as compared to other antiepileptic medications (Vining, 1987). Like CBZ,
VPA also has a low incidence of EPS and renal side effects. However, VPA rarely causes thyroid,
cardiac, dermatologic, or allergy effects unlike CBZ. Most side effects of VPA are dose related and
include gastrointestinal disturbance, sedation, tremor, and weight fluctuations. Weight gain is the
most common side effect and seen in approximately half of individuals taking VPA (Diamond,
2002). Other common side effects that tend to disappear after a few weeks are nausea, vomiting,
and indigestion. Although sedation is a side effect of VPA, it is less common than with CBZ
(McElroy & Keck, 1995). More serious side effects are liver toxicity in children and pancreatitis.
It is evident that each class of medication and each medication within each class have varying
therapeutic effects and side effects associated with them that need to be considered when deciding if
and which medication may be right for an individual. As mentioned previously, there are several
guidelines and medication algorithms available to aide clinicians in their choice of medication.
However, often other factors also play a part in the decision to use psychotropic medications. For
example, individuals in large institutions have been shown to receive more antipsychotic medications
than the general population, especially individuals with mental retardation. The variance in
prescribing practices across populations is due to a number of reasons ranging from physicians
personal preference to the presence of a drug company representative to the type of symptomology
being treated. Given the number of medications available and the uses for each, it is important to
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look at the reasons behind the use of respective psychotropic medications and the appropriateness
of their usage in each population.
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USE OF PSYCHOTROPIC MEDICATION
Given the prevalence and specificity of psychotropic medications, the question of
appropriate usage arises. The most common reason for psychotropic medication use is for the
management of behavioral problems (Clarke, Kelly, Thinn, & Corbett, 1990; Coughlan, 2000;
Molyneaux, Emerson, & Caine, 1999; Stolker, Heerdink, Leufkens, Clerkx, & Nolen, 2001).
However, authors such as Aman and Singh (1988), Baumeister, Sevin, and King (1998) and Gadow
and Poling (1988) have described such practices as controversial for the following reasons: (1) there
is limited evidence suggesting that such drugs are actually effective in reducing behavior problems,
and (2) the adverse effects of antipsychotic medications that produce changes in central and
autonomic nervous system functioning, including tardive dyskinesia, akathisia, and other disorders.
Further, several studies have reported that the withdrawal or reduction of antipsychotic medication
had either beneficial or, at least, neutral effects on behavior and increased skill acquisition (Davis et
al., 1998; La Mendola, Zaharia, & Carver, 1980; Luchins, Dojka, & Hanrahan, 1993).
When using psychotropic medications to treat behavioral symptoms, clinicians should follow
specific treatment guidelines or test a specific behavioral-pharmacological hypothesis. The former
involves the use of specific guidelines or an algorithm to determine the best course of medication
for an individual given certain measurable factors such as age, race, diagnosis, and response to
treatment. In the latter case, the clinician may suspect that an individual’s behavioral presentation is
a manifestation of an underlying physiological disorder. For example, a dysfunction of the
endogenous opioid system has been implicated in the etiology of self-injury. Thus, an imbalance in a
neurotransmitter system is manifested behaviorally as self-injury. The hypothesis is that an
individual will engage in self-injury to elevate his level of endogenous opioids, thereby receiving a
pleasurable response. This suggests that the primary treatment would be psychopharmacological
rather than behavioral. However, a behavioral training program consisting of vigorous, regular
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exercise may be used as an adjunctive therapy because it too assists in the elevation of endogenous
opioids—the so-called “runner’s high” or “being in the zone” effect. Nonetheless, most individuals
with mental retardation will not engage in exercise at a consistent level that will produce an increase
in their endogenous opioids, so a pharmacological intervention would be the treatment of choice,
with adjunctive behavior therapy.
In addition to the presence of behavioral and physiological problems, several other
predictive variables that contribute to the use of such drugs among individuals with mental
retardation have been identified. Demographic variables that have not been associated with an
increase in psychotropic medication use in this population are race/ethnicity (Cullinan, Gadow, &
Epstein, 1987) and gender (Singh et al., 1997). However, variables such as age, severity of mental
retardation, and the restrictiveness and size of facility have all been associated with the use of
psychotropic medications (Singh et al., 1997). In some studies, age has been positively correlated in
older populations, specifically middle-aged adults (Jacobson, 1988), while in others age has been
found to have no effect (Stolker et al., 2001). In addition, the severity of an individual’s mental
retardation has been shown to have an effect on the use of psychotropic medications. Generally,
the more severe the individuals’ disability, the greater number and higher the dosage of medications
prescribed (Aman, Sarphare, & Burrow, 1995; Jacobson, 1988). Finally, the size and restrictiveness
of the facility is highly correlated with medication use with the highest effect being in larger and
more restrictive facilities; these findings hold across both community and institutional settings
(Aman, Field, & Bridgman, 1985; Singh et al., 1997; Singh & Winton, 1989).
Not surprisingly, psychiatric diagnosis is highly correlated with the use of psychotropic
medications in both individuals with and without mental retardation. While the efficacy of
medication to treat specific psychiatric disorders has been well established in the literature with
individuals without mental retardation, there is a paucity of such literature regarding individuals with
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mental retardation and developmental disabilities. Of the literature available, most studies tend to
focus on the use of antipsychotic medications to treat behavioral problems rather than on
psychiatric symptomology and their use tends to be based on weak scientific evidence (Singh et al.,
1997). When comparing the use of psychotropic medications among individuals with and without
mental retardation, there is a higher prevalence of drug use in the former population (Jacobson,
1988; Intagliata & Rinck, 1985; Stolker et al., 2001). However, the appropriateness of these
prescriptions remains questionable given the difficulty in diagnosing psychiatric disorders in most
individuals with mental retardation.
Given that several factors have been identified that predict the use of psychotropic
medications, the question remains as to the appropriateness of drug usage. Indeed, if these variables
predict drug use, are there specific guidelines being followed or a behavioral-pharmacological
hypothesis being tested? If the answer is “No,” then the use of psychotropic medications to treat
psychiatric disorders and behavior problems among individuals with mental retardation becomes
one of trial and error. If a drug is to be used, there must be a hypothesized mechanism as to why a
particular drug would produce beneficial effects, or there is evidence that the specific psychiatric
disorder being targeted is medication responsive.
Bates et al., (1986) reported the first study that examined the appropriateness of
psychotropic medication usage among this population. They evaluated the appropriateness of
psychotherapeutic medications regimens of 242 individuals with mental retardation residing in
institutionalized settings in Ohio. The sample consisted of 108 women and 134 men who ranged in
age from 16 to 78 and in level of retardation from mild to profound. Specifically, Bates et al.
examined the relationship between medication regimens and psychiatric diagnosis according to
standards for the treatment of specific psychiatric diagnoses for individuals without mental
retardation. The standards used in this study were based on the Manual for Psychiatric Peer Review
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(APA, 1981), as well as textbooks in psychiatry (Kaplan & Sadock, 1984) and psychopharmacology
(Klein, Gittelman, Quitkin, & Rafkin, 1980). According to the standards used, 45.4% to 60.9% of
the medication regimens evaluated were rated as appropriate while 39.1% to 54.6% were rated as
inappropriate across settings.
Young and Hawkins (2002) reported the only other study to examine the reasons individuals
with mental retardation are prescribed psychotropic medication. They examined the psychotropic
medication regimens of 71 individuals with mental retardation receiving services from a community
based mental health/mental retardation center in Texas. The individuals in this survey ranged in age
from 18 to 80 and included 42 males and 29 females, whose level of mental retardation ranged from
mild to profound. To determine the appropriateness of each medication regimen as it related to the
individual’s psychiatric diagnosis, the authors used prescribing guidelines set forth in the Clinical
Handbook of Psychotropic Drugs (Bezchlibnyk-Butler, & Jeffries, 1996) for individuals without
mental retardation. Based on the standards used, 59% of the medication regimens examined were
considered appropriate for the targeted diagnosis while 20% were considered inappropriate. These
results compared fairly well to those of Bates et al. (1986), especially in terms of the appropriateness
of drug prescriptions. Although the inappropriate use of medications was lower in this study, it still
suggested that many individuals with developmental disabilities were receiving psychotropic
medications not based on rational pharmacotherapy.
These two studies advanced our understanding of drug therapy for people with mental
retardation beyond looking at the prevalence and patterns of drug therapy. They forged a new
direction in our research by focusing at the appropriateness of the drug prescription. While the
prevalence and patterns of drug prescriptions gives us an overall view of the field, it does little to tell
us whether rational pharmacotherapy is taking place. We need to know how drug prescription
decisions are made.
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PURPOSE
The purpose of this study was to examine the approaches taken in prescribing psychotropic
drugs to individuals with mental retardation in one state facility. As stated previously, there are three
ways of conceptualizing psychopharmacotherapy in people with mental retardation that can be
documented. Currently, there is no literature on this subject and it remains unclear how physicians
are conceptualizing the use of psychopharmacological regimens in individuals with mental
retardation. The hypothesis of this study is that the three approaches (primary illness, target
symptom, and behavioral-pharmacologic) are used equally. In addition to the primary hypothesis,
additional analyses will be conducted to examine the presence of any patterns or predictors of
psychopharmacology in this sample of individuals with mental retardation.
It behooves us to assess how psychotropic medications are prescribed in people with mental
retardation and developmental disabilities. Researchers have shown that the prevalence of
psychotropic medication use among individuals with mental retardation is relatively high when
compared to people with other disabilities and that the reasons for these drug prescriptions may not
be based on rational pharmacotherapy (Bates et al., 1985; Young & Hawkins, 2002). We need data
on the prescribing physician/psychiatrist’s adherence to consensus guidelines or algorithms
developed to enhance rational psychopharmacotherapy. However, in order to do this we must first
examine the rationales being used by physicians when they decide to prescribe a medication. From
this line of research, instruments and algorithms could be developed that are based on scientific
evidence and current best practice to aid clinicians in their treatment selection and provide a bridge
between the research literature and clinical practice in the area of psychopharmacology of
developmental disabilities.
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METHOD
Sample
The sample consisted of individuals residing at Pinecrest Developmental Center (PDC) in
central Louisiana. PDC is the largest state-supported residential developmental and training facility
in Louisiana. The center provides services to approximately 584 individuals with varying degrees of
mental retardation and types of developmental disabilities. Individuals range in age from 8 to 92
years, and each individual is provided active treatment through a ‘Learning-Based Supports’ Plan
developed by the individual’s interdisciplinary team. The subset of individuals that are the focus of
this study are residents on psychotropic medication for behavior problems or psychiatric disorders
(n = 87).
Procedure
Data on the 87 study participants were collected through the PDC client database and a
chart review of the individuals on psychotropic medications. Medications were those prescribed for
their psychotropic effects with the aim of controlling problem behaviors or specific mental health
disorders. Antiepileptic drugs (AEDs) prescribed specifically for seizure disorders were not counted
as psychotropic drugs. AEDs prescribed for their psychotropic effects for controlling behavior
problems (e.g., aggression) or psychiatric symptoms (e.g., mood) were counted as psychotropic
drugs.
Data Collection
In the first step of data collection, the primary researcher collected all sociodemographic
data from the PDC client database for each of the 87 individuals who were prescribed psychotropic
medications. Data were comprised of the following elements: name, age, age group, gender, race,
primary Axis I diagnosis, disorder type, level of mental retardation, medication, medication type,
approach type, number of target symptoms and specific target symptoms. The demographic
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variables of interest in this study have shown to be correlated with psychotropic medication use
(Aman et al., 1995; Aman & Singh, 1988; Bisconer et al., 1996; Singh et al., 1997; Young & Hawkins,
2002).
In the second step of data collection, the clinical decision-making of the prescribing
physician was determined in terms of approaches outlined previously, namely: (a) a target symptom
approach, (b) a primary illness approach, and (c) a behavioral-pharmacologic hypothesis approach.
A fourth category (i.e., no apparent approach) was also included for cases where there was no clear
or documented evidence of a specific approach being taken by the physician. The approach chosen
by the prescribing physician for each drug prescription was obtained from each individual’s
“Learning-Based Supports” Plan - specifically from the Medication Plan section.
The following algorithm was used as a guide by both the primary and secondary researchers
to determine which of the three approaches was used by the prescribing physician:
a. Is the target symptom approach used? Yes, if:
I.

Specific behaviors, such as aggression or self-injury, are listed as the target of
medication treatment

b. Is a primary illness approach used? Yes, if:
I. A psychiatric disorder, or specific signs and symptoms of a psychiatric
disorder, is the listed focus of medication intervention
c. Is a behavioral-pharmacological hypothesis approach used? Yes, if:
I.

A specific biological dysregulation is listed as the cause of the behavior being
treated with medication

d. If none of the above approaches is used, then:
I. The prescription was counted as “no apparent approach” for analysis
purposes.
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Data Analysis/Research Design
In the first part of this analysis, demographic data were summarized to determine the
characteristics of the sample population. In the second part of this analysis, the approaches taken by
the prescribing physicians were examined. A Chi Square procedure was used to test the primary
hypothesis and determine if there were any significant differences between the observed and
expected frequencies of each approach type. The expected value for each approach type was set at
29 (33.3%) because it was predicted each of the approaches (i.e., target symptom, primary illness,
and behavioral-psychopharmacological hypothesis) would be used equally. In addition, crosstabulations were conducted to examine any patterns in the data regarding approach type by gender,
race, diagnosis, level of mental retardation, medication type, and age group.
Inter-rater Reliability
A second rater was trained by the primary researcher on how to collect the data. The
primary investigator devised ten sample datasets representative of data that would be found in an
individual’s chart and in the PDC database. One of these sample datasets was used for training
where both researchers collected data at the same time. The remaining datasets were used as
independent reliability checks. When 100% agreement was achieved on three of the sample data
sets the additional rater was considered trained.
The primary researcher collected all the socio-demographic data on each of the 87
individuals receiving psychotropic medications. The primary researcher and the secondary rater
collected the same data on 20% (n = 17) of randomly selected individuals from the total sample (N
= 87) to determine interrater reliability. Inter-rater reliability was calculated using Cohen’s Kappa
because this method was specifically developed to measure inter-rater reliability of categorical data
(Cohen, 1960, 1968; Hartmann, 1977). The reliability coefficient (Kappa) between the primary
researcher and the second rater was .92.
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RESULTS
There were 87 participants with mental retardation who were prescribed at least one
psychotropic medication for the treatment of an Axis I psychiatric diagnosis or a target behavior
problem. Table 1 presents the demographic characteristics of the sample population.
To examine differences between the observed frequency of the approach types and the
expected frequencies of the approach types a chi square analysis was conducted. As shown in Table
2, the chi square indicated a significant difference between the observed and expected frequencies of
the approach types x2(2, N = 87) = 115.76, p = .05. Thus, the hypothesis that each approach type
would be used equally does not hold. In prescribing medication for the psychiatric disorders,
physicians used the primary illness approach with 75 (86%) of the 87 individuals. They used the
target symptom approach with 9 (10%) individuals and no apparent rationale with another 3 (4%).
They did not use the behavioral-pharmacological approach at all.

Table 1. Demographic characteristics
Characteristic

Frequency

Percentage

18-41

14

16.1

42-65

58

66.7

66-87

15

17.2

Female

38

43.7

Male

49

56.3

Age

Gender

(table continued)
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Race
African-American

16

18.4

Caucasian

71

81.6

Mild

4

4.6

Moderate

11

12.6

Severe

13

14.9

Profound

54

62.1

Unspecified

5

5.8

Anxiety Disorder

13

14.9

Childhood Disorder

10

11.5

Mood Disorder

52

59.8

Psychotic Disorder

12

13.8

Anti-Anxiety

6

6.9

Antidepressant

27

31.0

Antipsychotic

37

42.5

Mood Stabilizer

17

19.5

Level of MR

Diagnosis Type

Medication Classes

Table 3 presents the Axis I diagnosis, signs and symptoms targeted by the medication, and
the class of medication prescribed for the disorder or target behavior. In 30 cases (35%), no signs
and symptoms of the disorder were specified and it was unclear as to what behavioral end-points of
the psychiatric disorder were being targeted by the psychopharmacology treatment plan. On the
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other hand, multiple symptoms (i.e., up to 8) were listed for a single psychiatric disorder and it was
unclear which symptoms were being targeted. While an assumption can be made that all listed
symptoms of the disorder were evident in the individual, there was often no supporting data in the
individual’s chart to verify this assumption.

Table 2. Chi Square for observed and expected frequencies of approach type.
Frequency
Approach Type

Observed

Expected

Primary Illness

75

29

Target Symptom

9

29

Behavioral-Pharmacological

0

29

Table 3. Primary Axis I diagnosis and symptoms targeted in psychopharmacology treatment plan.
Subject

Primary Axis I Diagnosis

Associated Symptoms

Number
1
2

Medication

Number of

Type

Symptoms

Stereotypic Movement Disorder

no diagnosis-specific symptoms listed

antidepressant

0

Bipolar I Disorder

decreased social contact, distractibility,

antipsychotic

5

mood stabilizer

5

antianxiety

7

psychomotor agitation, restlessness,
constant movement
3

Bipolar Disorder, NOS

irritability, social isolation, psychomotor
agitation, weight loss, impulsivity

4

Generalized Anxiety Disorder

pacing, difficulty sitting still, fidgeting,
yelling, screaming, worrying, irritability

(table continued)
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5

Bipolar I Disorder

crying, psychomotor agitation, increase in

antipsychotic

3

goal-directed activity
6

Mood Disorder, NOS

no diagnosis-specific symptoms listed

antidepressant

0

7

Depressive Disorder, NOS

crying, irritability, social withdrawal

antidepressant

3

8

Anxiety Disorder, NOS

no diagnosis-specific symptoms listed

mood stabilizer

0

9

Bipolar I Disorder

agitation, driven motor activity, irritability,

antipsychotic

4

antipsychotic

5

poor sleep
10

Schizoaffective Disorder

delusions, hallucinations, emotional
lability, crying, depression

11

Anxiety Disorder, NOS

fidgeting

antidepressant

1

12

Major Depressive Disorder

crying, irritability, psychomotor agitation

antidepressant

3

13

Dysthymic Disorder

sad affect, crying, increased sleep, fatigue,

antidepressant

6

irritability, decreased interest
14

Bipolar I Disorder

no diagnosis-specific symptoms listed

mood stabilizer

0

15

Psychotic Disorder, NOS

no diagnosis-specific symptoms listed

antipsychotic

0

16

Bipolar I Disorder

increased activity, decreased judgment,

antipsychotic

3

poor sleep
17

Schizophrenia

no diagnosis-specific symptoms listed

antipsychotic

0

18

Schizophrenia

no diagnosis-specific symptoms listed

antipsychotic

0

19

Bipolar I Disorder

decreased sleep, increased activity,

mood stabilizer

3

excessive vocalizations
20

Psychotic Disorder, NOS

no diagnosis-specific symptoms listed

antipsychotic

0

21

Bipolar Disorder, NOS

psychomotor agitation, decreased sleep,

mood stabilizer

6

antipsychotic

3

impulsivity, increased activity, crying,
excessive vocalizations
22

Tourette's Disorder

rapid eye blinking, lip popping, head
twitching

(table continued)
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23

Bipolar I Disorder

increased activity, decreased sleep,

mood stabilizer

4

irritability, aggression, impulsivity

antipsychotic

3

irritability, sleep disturbance,

antidepressant

4

elevated mood, irritability
24

Disruptive Behavior Disorder,
NOS

25

Mood Disorder, Depressed

psychomotor agitation, depressed mood
26

Bipolar Disorder, NOS

no diagnosis-specific symptoms listed

antipsychotic

0

27

Bipolar I Disorder

irritability, psychomotor agitation, sleep

antipsychotic

3

disturbance
28

Bipolar I Disorder

no diagnosis-specific symptoms listed

antipsychotic

0

29

Bipolar I Disorder

irritability, psychomotor agitation,

mood stabilizer

4

antipsychotic

6

mood stabilizer

3

antidepressant

4

mood stabilizer

3

no diagnosis-specific symptoms listed

antipsychotic

0

pressured speech, poor concentration
30

Bipolar I Disorder

lethargy, decreased appetite, decreased
interactions, irritability, sleep disturbance,
increased speech

31

Bipolar I Disorder

psychomotor agitation, irritability,
decreased sleep

32

Dysthymic Disorder

depressed mood, decreased energy,
crying, psychomotor agitation

33

Bipolar I Disorder

psychomotor acceleration, sleep
disturbance, impulsivity

34

Disruptive Behavior Disorder,
NOS

35

Psychotic Disorder, NOS

no diagnosis-specific symptoms listed

antipsychotic

0

36

Bipolar I Disorder

no diagnosis-specific symptoms listed

mood stabilizer

0

37

Psychotic Disorder, NOS

no diagnosis-specific symptoms listed

antipsychotic

0
(table continued)
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38

Bipolar I Disorder

psychomotor agitation, decreased sleep,

antidepressant

3

mood stabilizer

4

crying
39

Bipolar I Disorder

increased activity, psychomotor
agitation, flat affect, sleep disturbance

40

Bipolar Disorder, NOS

psychomotor agitation

antipsychotic

1

41

Bipolar I Disorder

psychomotor agitation, impulsivity,

antipsychotic

4

reduced sleep, increased vocalizations
42

Schizophrenia

no diagnosis-specific symptoms listed

antipsychotic

0

43

Schizoaffective Disorder

no diagnosis-specific symptoms listed

antipsychotic

0

44

Bipolar I Disorder

psychomotor agitation, sleep disturbance,

antipsychotic

4

crying
45

Generalized Anxiety Disorder

worrying

antidepressant

1

46

Stereotypic Movement Disorder

skin picking, hand shaking

antipsychotic

2

47

Generalized Anxiety Disorder

worrying, restlessness, decreased sleep,

antianxiety

4

irritability
48

Mood Disorder, NOS

no diagnosis-specific symptoms listed

antidepressant

0

49

Schizophrenia

attending to internal stimuli, bizarre

antipsychotic

4

motor posturing, paranoia, flat affect
50

Depressive Disorder, NOS

crying, irritability, poor sleep

antidepressant

3

51

Anxiety Disorder, NOS

worrying, nervousness

antianxiety

2

52

Major Depressive Disorder

no diagnosis-specific symptoms listed

antidepressant

0

53

Bipolar I Disorder

agitation, decreased sleep, increased

mood stabilizer

3

motor activity
54

Bipolar Disorder, NOS

no diagnosis-specific symptoms listed

antipsychotic

0

55

Bipolar Disorder, NOS

hypersomnia, weight loss, irritability,

antidepressant

5

decreased engagement, social withdrawal
(table continued)
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56

Bipolar Disorder, NOS

irritability, psychomotor agitation, sleep

mood stabilizer

3

disturbance
57

Post Traumatic Stress Disorder

no diagnosis-specific symptoms listed

antidepressant

0

58

Psychotic Disorder, NOS

no diagnosis-specific symptoms listed

antipsychotic

0

59

Pica

no diagnosis-specific symptoms listed

antidepressant

0

60

Intermittent Explosive Disorder

no diagnosis-specific symptoms listed

antidepressant

0

61

Bipolar I Disorder

decreased sleep, psychomotor agitation,

antipsychotic

3

antipsychotic

4

crying, weight loss
62

Bipolar Disorder, NOS

psychomotor agitation, elevated mood,
decreased sleep, irritability

63

Stereotypic Movement Disorder

no diagnosis-specific symptoms listed

antipsychotic

0

64

Obsessive-Compulsive Disorder

hoarding, repetitive cleaning

antidepressant

2

65

Post Traumatic Stress Disorder

repeatedly discussing past abuse,

antidepressant

6

antianxiety

4

nightmares, avoidance, exaggerated
startle response, trembling
66

Anxiety Disorder, NOS

sleep disturbance, irritability, restlessness,
muscle tension

67

Bipolar I Disorder

no diagnosis-specific symptoms listed

antipsychotic

0

68

Depressive Disorder, NOS

depressed mood, crying, irritability,

antidepressant

6

antipsychotic

3

insomnia, fatigue, psychomotor retardation
69

Bipolar I Disorder

decreased sleep, psychomotor agitation,
social withdrawal

70

Psychotic Disorder, NOS

hallucinations, paranoia

antipsychotic

2

71

Bipolar Disorder, NOS

easily distracted, extremely talkative,

antipsychotic

4

antianxiety

0

irritability, psychomotor agitation
72

Anxiety Disorder, NOS

no diagnosis-specific symptoms listed

(table continued)
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73

Bipolar I Disorder

decreased sleep, crying, psychomotor

mood stabilizer

3

agitation
74

Anxiety Disorder, NOS

restlessness

antidepressant

1

75

Bipolar II Disorder

sleep disturbance, distractibility,

antipsychotic

3

psychomotor agitation
76

Major Depressive Disorder

social isolation

antidepressant

1

77

Bipolar Disorder, NOS

decreased sleep, irritability, increased

mood stabilizer

4

antidepressant

8

antidepressant

5

activity, pressured speech
78

Major Depressive Disorder

irritability, anhedonia, sleep disturbance,
lethargy, depressed mood, decreased
appetite, distractibility, social withdrawal

79

Major Depressive Disorder

psychomotor agitation, depressed mood,
crying, sleep disturbance, lack of interest

80

Mood Disorder, NOS

no diagnosis-specific symptoms listed

antipsychotic

0

81

Major Depressive Disorder

irritability, restlessness, social isolation,

antidepressant

5

antidepressant

5

weight loss, psychomotor retardation
82

Depressive Disorder, NOS

social isolation, irritability, decreased
appetite, decreased interest, lethargy

83

Pica

no diagnosis-specific symptoms listed

antianxiety

0

84

Bipolar I Disorder

no diagnosis-specific symptoms listed

mood stabilizer

0

85

Stereotypic Movement Disorder

no diagnosis-specific symptoms listed

antipsychotic

0

86

Bipolar II Disorder

sleep disruption, agitation, decreased

mood stabilizer

3

antidepressant

3

appetite
87

Anxiety Disorder, NOS

restlessness, poor attention, low
concentration

Table 4 presents the Axis I psychiatric diagnosis and the specific medications prescribed for
each of them by the number of individuals with each of the disorders. Especially for those more
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frequently occurring disorders, there was no clear information in each individual’s medical chart why
one drug was chosen over another.
Cross tabulation analyses were conducted to explore any relationships among the data
collected. These analyses showed that of the 75 cases following a primary illness approach, 47
(62.7%) had a diagnosis of a mood disorder, 11 (14.7%) had a diagnosis of an anxiety disorder, 9
(12%) had a diagnosis of a psychotic disorder and 8 (10.7%) had a diagnosis of a childhood disorder.
Of these 75 cases, 47 (62.7%) were individuals with profound mental retardation, 12 (16%) with
severe mental retardation, 8 (10.7%) with moderate mental retardation, 4 (5.3%) with mild mental
retardation and 4 (5.3%) with unspecified level of mental retardation. In 31 (41.3%) cases, the
individuals were prescribed an antipsychotic medication, 24 (32%) were prescribed an antidepressant, 14 (18.7%) a mood stabilizer and 6 (8%) were prescribed an anxiolytic. Further, 11 of
the 75 individuals (14.7%) were between the ages of 18 and 41, 49 (65.3%) were between the ages of
42 and 65, and 15 (20%) were between the ages of 66 and 87. Of the 75, 60 (80%) individuals were
Caucasian and 15 (20%) were African Americans; 35 (46.7%) were females.

Table 4. Diagnosis and medications prescribed by approach taken.
Primary Illness Approach
Primary Diagnosis

Medication Prescribed

Total

Buspar (3)

6

Anxiety Disorder, NOS

Luvox (1)
Remeron (1)
Zoloft (1)
(table continued)
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Bipolar Disorder, NOS

Depakote (2)

9

Lithium (1)
Olanzapine (2)
Paxil (1)
Risperidone (2)
Tegretol (1)
Bipolar I Disorder

Abilify (2)

22

Depakote (4)
Lithium (1)
Neurontin (1)
Olanzapine (8)
Prozac (1)
Risperidone (1)
Seroquel (1)
Tegretol (3)
Bipolar II Disorder

Depakote (1)

2

Olanzapine (1)
Depressive Disorder, NOS

Paxil (1)

3

Remeron (1)
Wellbutrin (1)
Disruptive Behavior Disorder, NOS

Depakote (1)

2

Risperidone (1)
(table continued)
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Dysthymic Disorder
Generalized Anxiety Disorder

Paxil (2)

2

Clonazepam (2)

3

Paxil (1)
Intermittent Explosive Disorder
Major Depressive Disorder

Depakote (1)

1

Celexa (1)

6

Pamelor (1)
Paxil (3)
Serzone (1)
Mood Disorder, Depressed

Paxil (1)

1

Mood Disorder, NOS

Prozac (2)

2

Obsessive-Compulsive Disorder

Luvox (1)

1

Clonazepam (1)

2

Pica

Luvox (1)
Post Traumatic Stress Disorder
Psychotic Disorder

Zoloft (1)

1

Olanzapine (4)

5

Seroquel (1)
Schizoaffective Disorder

Olanzapine (1)

1

Schizophrenia

Olanzapine (2)

3

Seroquel (1)
Stereotypic Movement Disorder

Risperidone (2)

2

Tourette’s Disorder

Risperidone (1)

1

Total

75
(table continued)
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Target Symptom Approach
Target Symptom

Medication Prescribed

Total

Aggression

Neurontin

1

Aggression

Lithium

1

Aggression

Olanzapine

1

Aggression

Abilify

1

Aggression

Risperidone

1

Hallucinations

Risperidone

1

Weight Loss

Mellaril

1

Sleep Disturbance

Zoloft

1

Olanzapine

1

Involuntary Movement
Total

9
No Apparent Approach
Primary Diagnosis

Medication Prescribed

Total

Stereotypic Movement Disorder

Luvox

1

Major Depressive Disorder, NOS

Zoloft

1

Depakote

1

Bipolar I Disorder
Total

3

Of the nine individuals whose psychopharmacology plan followed a target symptom
approach, 3 (33.3%) had a diagnosis of a mood disorder, 3 (33.3%) had a diagnosis of a psychotic
disorder, 2 (22.2%) had a diagnosis of an anxiety disorder, and 1 (11.1%) had a diagnosis of a
childhood disorder. Six (66.7%) individuals were diagnosed with profound mental retardation, 2
(22.2%) with moderate mental retardation, and 1 (11.1%) with severe mental retardation. An

55

antipsychotic was prescribed to 6 (66.7%) of these 9 individuals. In 2 (22.2%) cases, the individual
was prescribed a mood stabilizer and in 1 (11.1%) case an antidepressant. Anxiolytic medications
were not prescribed in this group. Further, 3 (33.3%) individuals were between the ages of 18 and
41 and 6 (66.7%) were between the ages of 42 and 65. and. Eight (88.9%) of the 9 individuals were
Caucasian and 1 (11.1%) was an African American; 8 (88.9%) were males.
Of those three individuals whose psychopharmacology plan followed an apparent approach,
2 (66.7%) had a diagnosis of a mood disorder and the other had a diagnosis of a childhood disorder.
One of these individuals was diagnosed with profound mental retardation, another was diagnosed
with moderate mental retardation and the third had an unspecified level of mental retardation. Two
individuals (66.7%) of were prescribed an antidepressant and the other individual was prescribed a
mood stabilizer. All three of these individuals were from the 42 to 65 age group, all three were
Caucasian, and 2 (66.7%) were female.
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DISCUSSION
The results showed that physicians at one facility for individuals with developmental
disabilities typically used a primary illness approach in prescribing psychotropic medication for Axis
I psychiatric disorders. Of the 87 individuals prescribed psychotropic medications for Axis I
psychiatric disorders, 75 of them had a psychopharmacology treatment plan derived from a primary
illness approach. This approach assumes that the behavioral end-points of the psychiatric disorder
can be managed, controlled or eliminated by treating the disorder itself. For example, aggression
arising from command hallucinations can be reduced or eliminated by treating hallucinations
without specifically targeting the aggression itself.
The primary illness approach provides clinicians with a method of conceptualizing an
individual’s treatment plan before they begin actual treatment. It enables an interdisciplinary
treatment team to determine how different symptoms and behaviors will be treated, and how to
integrate psychopharmacological, behavioral and other treatments. For example, when presented
with an individual who has an Axis I diagnosis of schizophrenia and an Axis II diagnosis of mild
mental retardation, the treatment team typically determines the nature and manifestations of the
schizophrenia in the individual prior to developing a treatment plan. The individual may present as
having command hallucinations that tell him to hurt himself and others, and is uncommunicative,
withdrawn, does not engage in activities of daily living skills (ADL skills), and is not motivated to
initiate or engage in assigned tasks.
In this case, the treatment team must decide if taking a primary illness approach will control
and manage his positive symptoms of schizophrenia (i.e., command hallucinations, aggression), as
well as his negative symptoms (i.e., uncommunicative, withdrawn, does not engage in activities of
daily living skills, and is not motivated to initiate or engage in assigned tasks). The physician may
determine that a drug prescription would be appropriate for the positive symptoms but that it may
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not greatly affect this individual’s negative symptoms. Thus, the team may use a primary illness
approach to treat the command hallucinations, thereby taking care of the aggression resulting from
command hallucinations. Thus, no behavioral intervention may be necessary specifically for
aggression. Further, the team may decide that while some benefits may accrue in the negative
symptoms due to the drug treatment for hallucinations, the negative symptoms are compounded
with the individual’s Axis II diagnosis of mental retardation and that there is an associated skills
deficit in communication, social skills and ADL skills. Thus, a target symptom approach would be
taken and the treatment plan includes skills training programs.
The primary illness approach works best in an integrated treatment planning system where
all disciplines provide input into the treatment plan. It also enhances the treatment team’s ability to
integrate different treatment modalities within a single treatment plan (Singh et al., 2002), particularly
behavioral and psychopharmacological. However, it does require the treatment team to have a good
understanding of the psychopharmacology of developmental disabilities in terms of Axis I
psychiatric disorders. For example, they need to know which drugs are effective with positive
symptoms, negative symptoms, or both. Current research suggests that the typical antipsychotic
medications target the positive symptoms of schizophrenia while the atypical antipsychotic
medications target both positive and negative symptoms, and, within the atypical group, Olanzapine
appears to be most effective with negative symptoms (Emsley & Oosthuizen, 2003). The typical
antipsychotics tend have more cognitive side effects such as memory and concentration problems,
trouble with executive functioning, and attention. Thus, physicians will need to have a good
working knowledge of the various effects and side effects of psychotropic medications so that they
can assist the treatment team to develop the best combination of treatments for specific disorders in
a given individual.
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The target symptom approach was used far less often, only 10% in this sample of 87
individuals. This approach assumes that there is a specific problem that needs treatment, and that
there is a specific treatment for the problem. This approach does not assume that the specific
treatment will also ameliorate the underlying psychopathology that is the cause of the problem
although it may. For example, in general medicine, an individual may present with fever that is high
enough to warrant immediate treatment regardless of the underlying medical condition that gave rise
to it. The fever is treated as a target symptom and brought under control while tests are undertaken
to find the cause of the fever. Sometimes, the cause of the fever may be apparent (e.g., recurrence
of cancer) but it cannot be treated and palliative medical treatment is provided for the cancer.
Similarly, in developmental disabilities, an individual may exhibit aggressive behavior that is
of high frequency and intensity and present a danger to self or others. The origin of the aggressive
behavior may be faulty learning and therefore treated via behavioral methods. This would be a good
example of a target symptom approach. An alternative would be that the aggressive behavior is a
manifestation of psychosis that is a part of the schizophrenia symptomatology of the individual. In
this case, because the aggressive behavior is dangerous to self or others and the psychosis is not well
controlled with current medication, a target symptom approach may be taken to control the
aggression while further tests and analyses are completed and a new psychopharmacology plan is
developed. A further alternative would be that the aggression is sometimes an outcome of the
psychosis and is an instrumental response at other times. In this case, a combined primary illness
and target symptom approach would be appropriate, as in combined pharmacological-behavioral
treatments.
In this facility, only 10% (n = 9) of the drug prescriptions were based on a target symptom
approach. However, it was unclear from the medical records of the nine individuals if the behaviors
targeted were only instrumental in nature or had any psychiatric symptoms. There was one specific
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case in which a target symptom approach was used with a behavior (i.e., hallucinations) that is
typically a symptom of psychosis. In this case, the hallucinations were unrelated to an Axis I
disorder and the symptom was treated pharmacologically as a target behavior. There were five cases
in which aggression was treated with psychotropic medication, but in each of these cases there was
an associated behavioral plan for the reduction of the instrumental component of the aggression.
What was not clear from the medical records was the underlying psychopathology of the aggression
that made the behavior responsive to medication. In one case, involuntary movement was
apparently treated with Olanzapine. It was not clear from the medical records why this drug was
deemed appropriate for this behavior.
The behavioral-pharmacological hypothesis approach provides clinicians a useful way of
conceptualizing treatment when there is clear empirical evidence that a certain drug may be effective
for a given behavior because there is a hypothesized mechanism of action that may account for the
effectiveness of the drug. For example, individuals with developmental disabilities engage in selfinjury for a variety of reasons, including biological, maladaptive learning, and environmental reasons
(Schroeder, Oster-Granite, & Thompson, 2002). There are two opiate hypotheses regarding selfinjury in some individuals and their treatment. In the first hypothesis, it is assumed that self-injury
results from general sensory depression and an insensitivity to pain that may be related to chronic
elevations of endogenous opiates (Sandman & Hetrick, 1995). In the second hypothesis, it is
assumed that self-injury functions to release β-endorphins and enables the individual to achieve an
opiate “high” (Sandman & Hetrick, 1995). In either case, the self-injury can be treated successfully
with opiate blockers, such as naloxone and naltrexone (Sandman et al., 2000). The behavioralpharmacological hypothesis was not used in this facility.
There were three cases where it was totally unclear as to the rationale used by the physician
to prescribe the psychotropic medication. The data in the individuals’ medical charts did not
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contain any psychopharmacology plan or an explanation of the reasons why the drugs were
prescribed.
In general, the documentation in the charts regarding assessments, diagnostic formulation,
differential diagnosis, and rationale of pharmacotherapy was not very clear or missing. Often, the
signs and symptoms of the disorders were listed but it was not made clear if the individual
manifested some or all of them. In many cases, the symptoms listed were generic and not
individualized. For example, for an individual with schizophrenia, the symptoms were listed as
auditory hallucinations, delusions, and thought disorder without any specifications as to the form
and content. In other cases, the listed symptoms did not comport to the given diagnosis. For
example, in one case, the single symptom listed for Major Depressive Disorder was social isolation.
It could be that all other symptoms were well controlled by medication and psychosocial
interventions or that the given diagnosis is open to question. Further, there were 30 (34.5%)
individuals with a “not otherwise specified” diagnosis. While this is a legitimate diagnosis, if it is
arrived at by eliminating all other possibilities that would account for the observed signs and
symptoms, there was very limited documentation of differential diagnosis leading to a “not
otherwise specified” diagnosis.
One of the limitations of this study is that there was no accounting for appropriate
assessment and diagnosis. It was assumed that appropriate assessments informed the diagnosis and
that the diagnosis informed further assessments for differential diagnosis. This was not assessed and
it is possible, at least for some individuals, that their diagnosis was incorrect, as reported in previous
studies (e.g., Bates et al., 1985), and that they were inappropriately medicated. Future studies should
investigate the accuracy of the diagnostic formulation and differential diagnosis.
Future studies should also investigate the appropriateness of the medications prescribed for
the purported diagnosis. In this study, it was noted that several medications were prescribed for
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given disorders and there was no clear rationale for choosing one drug over another. In one of the
few studies that investigated this issue in a small sample of individuals, it was found that there were
mismatches between the disorder and the drug prescribed (Young & Hawkins, 2002). Further
studies are needed to corroborate this finding. In addition, given that the field of
psychopharmacology in developmental disabilities now has a psychopharmacology consensus
handbook (Reiss & Aman, 1998) as well as expert consensus guidelines (Rush & Frances, 2002), it is
an opportune time to use these as the basis for determining the quality of the match between the
diagnosis and the prescribed medication.
In summary, the results of this study showed that physicians at one developmental center
rely mainly on a primary illness approach to prescribe psychotropic medication to individuals with
developmental disabilities who have an Axis I psychiatric disorder. To a much lesser extent, they
use a target symptom approach. No variables were apparent that predicted the use of a specific
approach with any specific individual.
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